A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Abstract Background This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly®), an infliximab biosimilar, vs infliximab (Remicade®) reference product sourced from the European...

Full description

Bibliographic Details
Main Authors: Stanley B. Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos, K. Lea Sewell
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Arthritis Research & Therapy
Subjects:
Infliximab
PF-06438179/GP1111
Biosimilar
Rheumatoid arthritis
Dose escalation
Online Access:http://link.springer.com/article/10.1186/s13075-018-1646-4

Internet

http://link.springer.com/article/10.1186/s13075-018-1646-4

Similar Items